Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2018 May 5

PMID 29725793

Citations 12

Authors

Antonio Facciorusso

Sunil Roy

Sarantis Livadas

Adwalia Fevrier-Paul

Clara Wekesa

Ismail Dogu Kilic

Amit Kumar Chaurasia

Mina Sadeq

Nicola Muscatiello

Affiliations

Soon will be listed here.

Abstract

Background: The role of nonselective beta-blockers in cirrhotic patients with ascites has been recently questioned; however, definitive evidence in this regard is still lacking.

Aims: To analyze published data on the influence of nonselective beta-blockers as compared to control group on survival of cirrhotic patients with ascites.

Methods: Computerized bibliographic search on the main databases was performed. Hazard ratios from Kaplan-Meier curves were extracted in order to perform an unbiased comparison of survival estimates. Secondary outcomes were mortality in patients with refractory ascites, pooled rate of nonselective beta-blockers interruption, spontaneous bacterial peritonitis and hepato-renal syndrome incidence.

Results: Three randomized controlled trials and 13 observational studies with 8279 patients were included. Overall survival was comparable between the two groups (hazard ratio = 0.86, 0.71-1.03, p = 0.11). Study design resulted as the main source of heterogeneity in sensitivity analysis and meta-regression. Mortality in refractory ascites patients was similar in the two groups (odds ratio = 0.90, 0.45-1.79; p = 0.76). No difference in spontaneous bacterial peritonitis (odds ratio = 0.78, 0.47-1.29, p = 0.33) and hepato-renal syndrome incidence (odds ratio = 1.22, 0.48-3.09; p = 0.67) was observed. Pooled rate of nonselective beta-blockers interruption was 18.6% (5.2-32.1%).

Conclusions: Based on our findings, nonselective beta-blockers should not be routinely withheld in patients with cirrhosis and ascites, even if refractory.

Citing Articles

The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension.

Xirouchakis E, Kranidioti H, Hadziyanni E, Kourikou A, Reppas C, Vertzoni M BMC Gastroenterol. 2024; 24(1):420.

PMID: 39574005 PMC: 11580216. DOI: 10.1186/s12876-024-03483-6.

Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.

Salcher-Konrad M, Nguyen M, Savovic J, Higgins J, Naci H JAMA Netw Open. 2024; 7(9):e2436230.

PMID: 39331390 PMC: 11437387. DOI: 10.1001/jamanetworkopen.2024.36230.

Advances in the management of complications from cirrhosis.

Singh J, Ebaid M, Saab S Gastroenterol Rep (Oxf). 2024; 12:goae072.

PMID: 39104730 PMC: 11299547. DOI: 10.1093/gastro/goae072.

Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis.

Xu X, Gao F, Wang T, Yang Z, Zhao Q, Qi X Ann Med. 2024; 56(1):2305935.

PMID: 38271554 PMC: 10812853. DOI: 10.1080/07853890.2024.2305935.

Fatty Liver Disease: Diagnosis and Stratification.

Saiman Y, Duarte-Rojo A, Rinella M Annu Rev Med. 2021; 73:529-544.

PMID: 34809436 PMC: 10074159. DOI: 10.1146/annurev-med-042220-020407.

References

Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P . Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology. 2015; 63(6):1968-76. DOI: 10.1002/hep.28352. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Ge P, Runyon B . When should the β-blocker window in cirrhosis close?. Gastroenterology. 2014; 146(7):1597-9. DOI: 10.1053/j.gastro.2014.04.028. View

Chirapongsathorn S, Valentin N, Alahdab F, Krittanawong C, Erwin P, Murad M . Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016; 14(8):1096-1104.e9. DOI: 10.1016/j.cgh.2016.01.012. View

Ge P, Runyon B . Treatment of Patients with Cirrhosis. N Engl J Med. 2016; 375(8):767-77. DOI: 10.1056/NEJMra1504367. View

Serste T, Melot C, Francoz C, Durand F, Rautou P, Valla D . Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52(3):1017-22. DOI: 10.1002/hep.23775. View

Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A . Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol. 2002; 37(3):315-21. DOI: 10.1016/s0168-8278(02)00174-5. View

Reiberger T, Ferlitsch A, Payer B, Mandorfer M, Heinisch B, Hayden H . Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2012; 58(5):911-21. DOI: 10.1016/j.jhep.2012.12.011. View

Garcia-Pagan J . Portal hypertension: Nonselective β-blockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol. 2010; 8(1):10-1. DOI: 10.1038/nrgastro.2010.185. View

10.

Leithead J, Rajoriya N, Tehami N, Hodson J, Gunson B, Tripathi D . Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2014; 64(7):1111-9. DOI: 10.1136/gutjnl-2013-306502. View

11.

Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, OLeary J . Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2017; 47(1):78-85. PMC: 6016372. DOI: 10.1111/apt.14366. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Cholongitas E, Papatheodoridis G, Manesis E, Burroughs A, Archimandritis A . Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?. J Gastroenterol Hepatol. 2006; 21(3):581-7. DOI: 10.1111/j.1440-1746.2005.03982.x. View

14.

Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G . The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2014; 35(2):362-9. DOI: 10.1111/liv.12593. View

15.

Escorsell A, Banares R, Garcia-Pagan J, Gilabert R, Moitinho E, Piqueras B . TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002; 35(2):385-92. DOI: 10.1053/jhep.2002.30418. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Lo G, Chen W, Chen M, Lin C, Lo C, Hsu P . Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc. 2004; 59(3):333-8. DOI: 10.1016/s0016-5107(03)02819-0. View

18.

Aday A, Mayo M, Elliott A, Rockey D . The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites. Am J Med Sci. 2016; 351(2):169-76. DOI: 10.1016/j.amjms.2015.11.018. View

19.

Facciorusso A, Di Maso M, Muscatiello N . Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis. 2016; 48(6):571-7. DOI: 10.1016/j.dld.2016.02.005. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View